Use of intravitreal triamcinolone acetonide has quickly gained favor among retinal specialists as a first-line treatment for treatment of macular edema associated with retinal vein occlusion (RVO). However, findings from an evidence-based literature review indicate published data to support what has become a widespread clinical phenomenon are broad but not deep, said Robert Bhisitkul, MD, PhD, at the World Ophthalmology Congress."The purpose of this analysis was to look beyond the clinical impression that this therapy results in improved vision and reduced macular thickness by considering its long- versus short-term clinical effects. Its results show our best available evidence is inconclusive at best, but results of ongoing studies should give us a greater level of confidence in using intravitreal triamcinolone to treat patients with RVO," said Dr. Bhisitkul, professor of clinical ophthalmology, University of California San Francisco, in the United States.